Stockreport

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

OS Therapies Incorporated  (OSTX) 
PDF NEW YORK--(BUSINESS WIRE)--OS Therapies Incorporated (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage bi [Read more]